Remove Drug Development Remove Drugs Remove Pharma Companies
article thumbnail

How AI will reshape pharma by 2025

Drug Target Review

Artificial intelligence (AI) has revolutionised many industries, yet its adoption in pharmaceutical drug development has been notably slower. For years, AI and machine learning (ML) were often dismissed as little more than advanced statistics with little practical value in drug development.

article thumbnail

Best CDMO Practices for Startups: Navigating the Complex World of Contract Development and Manufacturing

Drug Patent Watch

Navigating the complex landscape of drug development and manufacturing can be a daunting task. Enter the Contract Development and Manufacturing Organization (CDMO) a lifeline for many startups looking to bring their innovative therapies to market. Your timeline will significantly impact your CDMO requirements.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Tackling complex manufacturing challenges in modern drug development

Drug Target Review

With a particular focus on biologics, cell, and gene therapies, Galbraiths work is centred on equipping drug developers with the tools, insights, and support needed to advance their therapies from concept to clinic. These innovative modalities present both exciting possibilities and unique challenges in drug discovery and development.

article thumbnail

Pharma Contract Sales Outlook 2025–2030: Multilingual Teams Drive Global Expansion

The Pharma Data

As pharma companies grapple with mounting pressure from regulators, payers, and evolving market dynamics, the CSO model offers a compelling alternative to traditional, fully in-house sales forces. These developments demand a highly skilled, therapeutically trained, and compliance-conscious salesforce —precisely what leading CSOs offer.

article thumbnail

Lessons from Monte Carlo Models: Why Drug Development is Hard

DrugBaron

But not everyone in drug development is playing this game. So what does the game look like to a late-stage investor or a pharma company head of R&D thinking about portfolio prioritisation? No wonder investing in drug development is so hard! But how do you know which game you are playing?

article thumbnail

Key Challenges of Specialty Pharma Drug Development Project Management

thought leadership

Specialty pharma companies are focused on developing drugs for niche markets, such as rare diseases , cancer, and other complex conditions. These drugs often require significant investment in research and development, and their development requires careful project management.

article thumbnail

Drug Repurposing: A New Life for Old Drugs

DrugBank

Drug repurposing is an approach that, while not new, has become popular in the last decade.   One of the most exciting prospects of drug repurposing is its potential to tackle "undruggable" targets—proteins or molecules that traditional drugs can't easily bind to.

Drugs 98